Cardiac ablation isn’t exactly a dinner party topic, unless you’re Field Medical, and your idea of a party is electrifying the heart (literally) with a tech platform that reimagines how we treat the most stubborn rhythm disorders out there.
On July 1st, the team at Field Medical dropped a Series B round that landed like a controlled thunderclap, $35 million, co-led by BioStar Capital and Cue Growth, with strong follow-through from existing strategic investors. Not a fluke. Not luck. It’s what happens when you build something with surgical precision and real-world urgency, and back it with a track record that reads like a blueprint for how to make waves in medtech without drowning in buzzwords.
Dr. Steven Mickelsen, MD, Founder and CEO, isn’t just an electrophysiologist; he’s the guy who invented pulsed field ablation (PFA). His first company, FARAPULSE, was scooped by Boston Scientific in 2021 for over $460M. Now he’s back, not to revisit the past, but to fix what’s still broken, ventricular tachycardia (VT), a deadly arrhythmia that medicine still treats with shrug-level success rates and legacy tech that doesn’t cut deep enough. Literally.
Field Medical’s weapon of choice? The FieldForce Ablation System, the first contact force focal PFA catheter built specifically for VT. Their secret sauce, FieldBending technology, lets them generate full-thickness lesions in fractions of a second. Translation: faster procedures, less time under fluoroscopy, and more patients walking out instead of flatlining. With their entry into the FDA’s Breakthrough Device program and inclusion in the TAP Pilot, the runway to regulatory clearance just got a whole lot shorter.
This $35M Series B fuels the start of VERITAS, a pivotal VT trial that could finally deliver clarity in a market where outcomes have been murky at best. The funding also sets the stage for scale, clinical expansion, international trial sites, and early prep for commercial rollout. Because let’s be honest, if half your patients aren’t responding to meds, it’s not a treatment. It’s a bet.
Big props to Oskar Dadason, CFO, for steering the financial engine, and board members Mark Wisniewski, Marlou Janssen, Dr. Alexei Mlodinow, and Ben Cannon for staying in the pocket and keeping the rhythm tight. On the investor side, Dr. Louis Cannon at BioStar Capital saw the vision early, and helped keep it sharp.
Field Medical isn’t angling to be the next big thing in ablation; they’re here to be the last word in VT. This round doesn’t just back a device. It backs a paradigm shift. And if you’re watching the medtech space from the sidelines, now might be a good time to lace up.
